People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

The rise of GLP-1 drugs is a reminder that we must move beyond the simple equation of thinness as health and value. These ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

In a new study, one nutrient made a difference in muscle loss for people losing weight on drugs like Ozempic. Here's what to eat to preserve your muscle on the meds.

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

With Gov. Patrick Morrisey’s first special session of 2025 likely to be focused on health care costs for public employees, lawmakers will have to contend with what to do about the Public Employees ...

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.